Terbinafine
1
Reactions 1478, p36 - 16 Nov 2013 S Terbinafine Subacute cutaneous lupus erythematosus: 2 case reports Two women, aged 43 years and 53 years, developed subacute cutaneous lupus erythematosus (SCLE) while receiving terbinafine. The younger woman, who had a history of systemic lupus erythematosus (SLE) controlled with methylprednisolone, was admitted with annular skin lesions, located mainly on the upper part of her body. The skin lesions had developed 8 weeks after starting oral terbinafine 250mg daily for onychomycosis of the toe nails. Terbinafine was withdrawn, while methylprednisolone was continued and mometasone was added. The lesions improved within 3 weeks. The older woman, who had a history of SLE controlled with methylprednisolone, was admitted due to severe erythematous lesions forming an annular arrangement on her trunk and limbs. The lesions had developed 3 weeks after starting oral terbinafine 250mg daily for nail tinea. Terbinafine had been withdrawn 3 days before admission. Methylprednisolone was increased and hydrocortisone was added. After 2 weeks, the skin lesions significantly improved, and methylprednisolone was reduced. The skin lesions cleared within the next 2 weeks. Author comment: "In this article we report two women with a many years’ history of SLE who developed SCLE after administering terbinafine." Kalinska-Bienias A, et al. Terbinafine-induced subacute cutaneous lupus erythematosus in two patients with systemic lupus erythematosus successfully treated with topical corticosteroids. Postepy Dermatologii i Alergologii 30: 261-264, No. 4, 2013. Available from: URL: http://dx.doi.org/10.5114/ pdia.2013.37038 - Poland 803095693 1 Reactions 16 Nov 2013 No. 1478 0114-9954/13/1478-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
Transcript of Terbinafine
Reactions 1478, p36 - 16 Nov 2013
STerbinafine
Subacute cutaneous lupus erythematosus: 2 casereports
Two women, aged 43 years and 53 years, developedsubacute cutaneous lupus erythematosus (SCLE) whilereceiving terbinafine.
The younger woman, who had a history of systemic lupuserythematosus (SLE) controlled with methylprednisolone, wasadmitted with annular skin lesions, located mainly on theupper part of her body. The skin lesions had developed8 weeks after starting oral terbinafine 250mg daily foronychomycosis of the toe nails. Terbinafine was withdrawn,while methylprednisolone was continued and mometasonewas added. The lesions improved within 3 weeks.
The older woman, who had a history of SLE controlled withmethylprednisolone, was admitted due to severeerythematous lesions forming an annular arrangement on hertrunk and limbs. The lesions had developed 3 weeks afterstarting oral terbinafine 250mg daily for nail tinea. Terbinafinehad been withdrawn 3 days before admission.Methylprednisolone was increased and hydrocortisone wasadded. After 2 weeks, the skin lesions significantly improved,and methylprednisolone was reduced. The skin lesions clearedwithin the next 2 weeks.
Author comment: "In this article we report two womenwith a many years’ history of SLE who developed SCLE afteradministering terbinafine."Kalinska-Bienias A, et al. Terbinafine-induced subacute cutaneous lupuserythematosus in two patients with systemic lupus erythematosus successfullytreated with topical corticosteroids. Postepy Dermatologii i Alergologii 30:261-264, No. 4, 2013. Available from: URL: http://dx.doi.org/10.5114/pdia.2013.37038 - Poland 803095693
1
Reactions 16 Nov 2013 No. 14780114-9954/13/1478-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
